nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—CYP3A4—type 2 diabetes mellitus	0.348	1	CbGaD
Avanafil—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0562	0.152	CbGbCtD
Avanafil—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0501	0.136	CbGbCtD
Avanafil—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0458	0.124	CbGbCtD
Avanafil—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.04	0.109	CbGbCtD
Avanafil—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0362	0.0982	CbGbCtD
Avanafil—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0274	0.0744	CbGbCtD
Avanafil—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0263	0.0713	CbGbCtD
Avanafil—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0263	0.0713	CbGbCtD
Avanafil—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0249	0.0675	CbGbCtD
Avanafil—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0185	0.0503	CbGbCtD
Avanafil—CYP3A4—Losartan—type 2 diabetes mellitus	0.017	0.046	CbGbCtD
Avanafil—PDE5A—penis—type 2 diabetes mellitus	0.013	0.412	CbGeAlD
Avanafil—PDE5A—artery—type 2 diabetes mellitus	0.00603	0.191	CbGeAlD
Avanafil—PDE5A—endothelium—type 2 diabetes mellitus	0.0051	0.161	CbGeAlD
Avanafil—PDE5A—retina—type 2 diabetes mellitus	0.00248	0.0784	CbGeAlD
Avanafil—PDE5A—cardiovascular system—type 2 diabetes mellitus	0.0021	0.0663	CbGeAlD
Avanafil—PDE5A—adipose tissue—type 2 diabetes mellitus	0.00185	0.0585	CbGeAlD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS1—type 2 diabetes mellitus	0.00148	0.0709	CbGpPWpGaD
Avanafil—CYP3A4—Felbamate Metabolism—CYP2E1—type 2 diabetes mellitus	0.00104	0.0498	CbGpPWpGaD
Avanafil—CYP3A4—Lidocaine metabolism—CYP1A2—type 2 diabetes mellitus	0.00103	0.0493	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—ATP2A3—type 2 diabetes mellitus	0.001	0.0481	CbGpPWpGaD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—type 2 diabetes mellitus	0.00088	0.0423	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—ATP2A2—type 2 diabetes mellitus	0.000719	0.0345	CbGpPWpGaD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS3—type 2 diabetes mellitus	0.000708	0.034	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—TRPC6—type 2 diabetes mellitus	0.000698	0.0335	CbGpPWpGaD
Avanafil—CYP3A4—kidney—type 2 diabetes mellitus	0.00064	0.0202	CbGeAlD
Avanafil—PDE5A—Platelet homeostasis—NOS1—type 2 diabetes mellitus	0.000575	0.0276	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—ABCC2—type 2 diabetes mellitus	0.000504	0.0242	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—GNB3—type 2 diabetes mellitus	0.000482	0.0231	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—APOB—type 2 diabetes mellitus	0.00046	0.0221	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—PPP2CA—type 2 diabetes mellitus	0.000412	0.0198	CbGpPWpGaD
Avanafil—CYP3A4—liver—type 2 diabetes mellitus	0.000404	0.0128	CbGeAlD
Avanafil—PDE5A—Hemostasis—GRB14—type 2 diabetes mellitus	0.000391	0.0187	CbGpPWpGaD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—type 2 diabetes mellitus	0.000377	0.0181	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—NOS2—type 2 diabetes mellitus	0.000343	0.0165	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—ABCC2—type 2 diabetes mellitus	0.000322	0.0154	CbGpPWpGaD
Avanafil—CYP3A4—Liver X Receptor Pathway—SREBF1—type 2 diabetes mellitus	0.000313	0.015	CbGpPWpGaD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—GSTM1—type 2 diabetes mellitus	0.000289	0.0139	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYB5R4—type 2 diabetes mellitus	0.000279	0.0134	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—NOS3—type 2 diabetes mellitus	0.000276	0.0132	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—type 2 diabetes mellitus	0.000276	0.0132	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—AANAT—type 2 diabetes mellitus	0.00025	0.012	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ATP2A3—type 2 diabetes mellitus	0.000224	0.0108	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA6—type 2 diabetes mellitus	0.000207	0.00995	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—type 2 diabetes mellitus	0.000197	0.00944	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—type 2 diabetes mellitus	0.000194	0.00933	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—THBD—type 2 diabetes mellitus	0.000191	0.00916	CbGpPWpGaD
Avanafil—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000191	0.000825	CcSEcCtD
Avanafil—Palpitations—Orlistat—type 2 diabetes mellitus	0.00019	0.000823	CcSEcCtD
Avanafil—Cough—Valsartan—type 2 diabetes mellitus	0.00019	0.000822	CcSEcCtD
Avanafil—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00019	0.000822	CcSEcCtD
Avanafil—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.00019	0.000821	CcSEcCtD
Avanafil—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.00019	0.00082	CcSEcCtD
Avanafil—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000189	0.000817	CcSEcCtD
Avanafil—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000188	0.000813	CcSEcCtD
Avanafil—Urinary tract infection—Ramipril—type 2 diabetes mellitus	0.000188	0.000813	CcSEcCtD
Avanafil—Cough—Orlistat—type 2 diabetes mellitus	0.000188	0.000812	CcSEcCtD
Avanafil—Flushing—Losartan—type 2 diabetes mellitus	0.000188	0.000812	CcSEcCtD
Avanafil—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000187	0.000811	CcSEcCtD
Avanafil—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000187	0.00081	CcSEcCtD
Avanafil—Vision blurred—Metformin—type 2 diabetes mellitus	0.000187	0.000809	CcSEcCtD
Avanafil—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000187	0.000808	CcSEcCtD
Avanafil—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000186	0.000806	CcSEcCtD
Avanafil—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000186	0.000805	CcSEcCtD
Avanafil—Myalgia—Valsartan—type 2 diabetes mellitus	0.000185	0.000802	CcSEcCtD
Avanafil—Chest pain—Valsartan—type 2 diabetes mellitus	0.000185	0.000802	CcSEcCtD
Avanafil—Arthralgia—Valsartan—type 2 diabetes mellitus	0.000185	0.000802	CcSEcCtD
Avanafil—Dizziness—Glipizide—type 2 diabetes mellitus	0.000185	0.000801	CcSEcCtD
Avanafil—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000185	0.0008	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000184	0.000797	CcSEcCtD
Avanafil—Angiopathy—Losartan—type 2 diabetes mellitus	0.000183	0.000794	CcSEcCtD
Avanafil—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000183	0.000794	CcSEcCtD
Avanafil—Myalgia—Orlistat—type 2 diabetes mellitus	0.000183	0.000793	CcSEcCtD
Avanafil—Chest pain—Orlistat—type 2 diabetes mellitus	0.000183	0.000793	CcSEcCtD
Avanafil—Epistaxis—Ramipril—type 2 diabetes mellitus	0.000182	0.000789	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000182	0.000787	CcSEcCtD
Avanafil—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000181	0.000784	CcSEcCtD
Avanafil—Sinusitis—Ramipril—type 2 diabetes mellitus	0.000181	0.000784	CcSEcCtD
Avanafil—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000181	0.000782	CcSEcCtD
Avanafil—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.00018	0.000778	CcSEcCtD
Avanafil—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000179	0.000775	CcSEcCtD
Avanafil—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000179	0.000773	CcSEcCtD
Avanafil—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000178	0.000771	CcSEcCtD
Avanafil—Vomiting—Glipizide—type 2 diabetes mellitus	0.000178	0.00077	CcSEcCtD
Avanafil—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000177	0.000767	CcSEcCtD
Avanafil—CYP3A4—Estrogen metabolism—CYP1A2—type 2 diabetes mellitus	0.000177	0.00849	CbGpPWpGaD
Avanafil—Infection—Valsartan—type 2 diabetes mellitus	0.000176	0.000764	CcSEcCtD
Avanafil—Rash—Glipizide—type 2 diabetes mellitus	0.000176	0.000764	CcSEcCtD
Avanafil—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000176	0.000763	CcSEcCtD
Avanafil—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000176	0.000763	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000176	0.000762	CcSEcCtD
Avanafil—Headache—Glipizide—type 2 diabetes mellitus	0.000175	0.000759	CcSEcCtD
Avanafil—Palpitations—Metformin—type 2 diabetes mellitus	0.000175	0.000758	CcSEcCtD
Avanafil—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000175	0.000757	CcSEcCtD
Avanafil—Infection—Orlistat—type 2 diabetes mellitus	0.000174	0.000755	CcSEcCtD
Avanafil—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000174	0.000754	CcSEcCtD
Avanafil—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000173	0.000747	CcSEcCtD
Avanafil—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000173	0.000747	CcSEcCtD
Avanafil—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000172	0.000745	CcSEcCtD
Avanafil—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000172	0.000745	CcSEcCtD
Avanafil—Agitation—Irbesartan—type 2 diabetes mellitus	0.000172	0.000744	CcSEcCtD
Avanafil—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000172	0.000744	CcSEcCtD
Avanafil—Hypertension—Metformin—type 2 diabetes mellitus	0.000171	0.000741	CcSEcCtD
Avanafil—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000171	0.000739	CcSEcCtD
Avanafil—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000171	0.000738	CcSEcCtD
Avanafil—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.00017	0.000738	CcSEcCtD
Avanafil—Back pain—Losartan—type 2 diabetes mellitus	0.00017	0.000737	CcSEcCtD
Avanafil—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.00017	0.000737	CcSEcCtD
Avanafil—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—type 2 diabetes mellitus	0.000169	0.00813	CbGpPWpGaD
Avanafil—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000169	0.000733	CcSEcCtD
Avanafil—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000169	0.000731	CcSEcCtD
Avanafil—Chest pain—Metformin—type 2 diabetes mellitus	0.000169	0.00073	CcSEcCtD
Avanafil—Myalgia—Metformin—type 2 diabetes mellitus	0.000169	0.00073	CcSEcCtD
Avanafil—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000168	0.000727	CcSEcCtD
Avanafil—Headache—Pioglitazone—type 2 diabetes mellitus	0.000168	0.000727	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000168	0.000725	CcSEcCtD
Avanafil—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000167	0.000722	CcSEcCtD
Avanafil—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000167	0.000722	CcSEcCtD
Avanafil—Nausea—Glipizide—type 2 diabetes mellitus	0.000166	0.000719	CcSEcCtD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—type 2 diabetes mellitus	0.000166	0.00797	CbGpPWpGaD
Avanafil—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000166	0.000719	CcSEcCtD
Avanafil—Hypotension—Valsartan—type 2 diabetes mellitus	0.000166	0.000718	CcSEcCtD
Avanafil—Vision blurred—Losartan—type 2 diabetes mellitus	0.000166	0.000718	CcSEcCtD
Avanafil—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000165	0.000716	CcSEcCtD
Avanafil—Constipation—Gliclazide—type 2 diabetes mellitus	0.000165	0.000716	CcSEcCtD
Avanafil—Rash—Glimepiride—type 2 diabetes mellitus	0.000165	0.000713	CcSEcCtD
Avanafil—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000164	0.000712	CcSEcCtD
Avanafil—CYP3A4—Xenobiotics—CYP2E1—type 2 diabetes mellitus	0.000164	0.00789	CbGpPWpGaD
Avanafil—Rash—Sitagliptin—type 2 diabetes mellitus	0.000164	0.00071	CcSEcCtD
Avanafil—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000164	0.00071	CcSEcCtD
Avanafil—Headache—Glimepiride—type 2 diabetes mellitus	0.000164	0.000708	CcSEcCtD
Avanafil—Cough—Irbesartan—type 2 diabetes mellitus	0.000163	0.000706	CcSEcCtD
Avanafil—Headache—Sitagliptin—type 2 diabetes mellitus	0.000163	0.000706	CcSEcCtD
Avanafil—CYP3A4—Xenobiotics—CYP1A2—type 2 diabetes mellitus	0.000163	0.00781	CbGpPWpGaD
Avanafil—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000162	0.000701	CcSEcCtD
Avanafil—Agitation—Losartan—type 2 diabetes mellitus	0.000162	0.0007	CcSEcCtD
Avanafil—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000162	0.000699	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ATP2A2—type 2 diabetes mellitus	0.000161	0.00774	CbGpPWpGaD
Avanafil—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000161	0.000698	CcSEcCtD
Avanafil—Flushing—Ramipril—type 2 diabetes mellitus	0.000161	0.000697	CcSEcCtD
Avanafil—Infection—Metformin—type 2 diabetes mellitus	0.000161	0.000696	CcSEcCtD
Avanafil—Insomnia—Valsartan—type 2 diabetes mellitus	0.000161	0.000695	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.00016	0.000692	CcSEcCtD
Avanafil—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000159	0.000689	CcSEcCtD
Avanafil—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000159	0.000689	CcSEcCtD
Avanafil—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000159	0.000689	CcSEcCtD
Avanafil—Insomnia—Orlistat—type 2 diabetes mellitus	0.000159	0.000687	CcSEcCtD
Avanafil—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000159	0.000687	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—type 2 diabetes mellitus	0.000158	0.0076	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP2E1—type 2 diabetes mellitus	0.000158	0.00759	CbGpPWpGaD
Avanafil—Vertigo—Losartan—type 2 diabetes mellitus	0.000158	0.000685	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000158	0.000685	CcSEcCtD
Avanafil—Somnolence—Valsartan—type 2 diabetes mellitus	0.000158	0.000684	CcSEcCtD
Avanafil—Skin disorder—Metformin—type 2 diabetes mellitus	0.000157	0.00068	CcSEcCtD
Avanafil—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000157	0.000678	CcSEcCtD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP1A2—type 2 diabetes mellitus	0.000156	0.00751	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TRPC6—type 2 diabetes mellitus	0.000156	0.00751	CbGpPWpGaD
Avanafil—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000156	0.000677	CcSEcCtD
Avanafil—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000156	0.000676	CcSEcCtD
Avanafil—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000156	0.000674	CcSEcCtD
Avanafil—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000156	0.000674	CcSEcCtD
Avanafil—Palpitations—Losartan—type 2 diabetes mellitus	0.000156	0.000673	CcSEcCtD
Avanafil—Nausea—Glimepiride—type 2 diabetes mellitus	0.000155	0.000671	CcSEcCtD
Avanafil—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000155	0.000669	CcSEcCtD
Avanafil—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000155	0.000669	CcSEcCtD
Avanafil—Asthenia—Glyburide—type 2 diabetes mellitus	0.000155	0.000669	CcSEcCtD
Avanafil—PDE5A—Hemostasis—F7—type 2 diabetes mellitus	0.000154	0.00738	CbGpPWpGaD
Avanafil—Cough—Losartan—type 2 diabetes mellitus	0.000154	0.000665	CcSEcCtD
Avanafil—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000153	0.000664	CcSEcCtD
Avanafil—Fatigue—Valsartan—type 2 diabetes mellitus	0.000153	0.000663	CcSEcCtD
Avanafil—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000153	0.000662	CcSEcCtD
Avanafil—Pruritus—Glyburide—type 2 diabetes mellitus	0.000152	0.000659	CcSEcCtD
Avanafil—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000152	0.000658	CcSEcCtD
Avanafil—Constipation—Valsartan—type 2 diabetes mellitus	0.000152	0.000658	CcSEcCtD
Avanafil—Infection—Irbesartan—type 2 diabetes mellitus	0.000152	0.000656	CcSEcCtD
Avanafil—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000152	0.000656	CcSEcCtD
Avanafil—Fatigue—Orlistat—type 2 diabetes mellitus	0.000151	0.000655	CcSEcCtD
Avanafil—Hypotension—Metformin—type 2 diabetes mellitus	0.000151	0.000654	CcSEcCtD
Avanafil—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000151	0.000653	CcSEcCtD
Avanafil—Myalgia—Losartan—type 2 diabetes mellitus	0.00015	0.000649	CcSEcCtD
Avanafil—Chest pain—Losartan—type 2 diabetes mellitus	0.00015	0.000649	CcSEcCtD
Avanafil—Arthralgia—Losartan—type 2 diabetes mellitus	0.00015	0.000649	CcSEcCtD
Avanafil—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.00015	0.000648	CcSEcCtD
Avanafil—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.00015	0.000648	CcSEcCtD
Avanafil—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000149	0.000645	CcSEcCtD
Avanafil—Rash—Bromocriptine—type 2 diabetes mellitus	0.000149	0.000643	CcSEcCtD
Avanafil—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000148	0.000642	CcSEcCtD
Avanafil—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000148	0.000642	CcSEcCtD
Avanafil—Headache—Bromocriptine—type 2 diabetes mellitus	0.000148	0.000639	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000147	0.000638	CcSEcCtD
Avanafil—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000147	0.000638	CcSEcCtD
Avanafil—Dry mouth—Losartan—type 2 diabetes mellitus	0.000147	0.000634	CcSEcCtD
Avanafil—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000145	0.000628	CcSEcCtD
Avanafil—Somnolence—Metformin—type 2 diabetes mellitus	0.000144	0.000622	CcSEcCtD
Avanafil—Infection—Losartan—type 2 diabetes mellitus	0.000143	0.000618	CcSEcCtD
Avanafil—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000143	0.000617	CcSEcCtD
Avanafil—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000142	0.000616	CcSEcCtD
Avanafil—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000141	0.00061	CcSEcCtD
Avanafil—Tachycardia—Losartan—type 2 diabetes mellitus	0.00014	0.000607	CcSEcCtD
Avanafil—CYP3A4—Farnesoid X Receptor  Pathway—PPARGC1A—type 2 diabetes mellitus	0.00014	0.00672	CbGpPWpGaD
Avanafil—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00014	0.000606	CcSEcCtD
Avanafil—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.00014	0.000604	CcSEcCtD
Avanafil—Fatigue—Metformin—type 2 diabetes mellitus	0.000139	0.000604	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000139	0.000602	CcSEcCtD
Avanafil—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000139	0.000601	CcSEcCtD
Avanafil—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000139	0.0006	CcSEcCtD
Avanafil—Agitation—Ramipril—type 2 diabetes mellitus	0.000139	0.0006	CcSEcCtD
Avanafil—Constipation—Metformin—type 2 diabetes mellitus	0.000138	0.000599	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ADRA2A—type 2 diabetes mellitus	0.000138	0.00661	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLAT—type 2 diabetes mellitus	0.000137	0.00658	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TIMP1—type 2 diabetes mellitus	0.000137	0.00658	CbGpPWpGaD
Avanafil—Vomiting—Glyburide—type 2 diabetes mellitus	0.000137	0.000593	CcSEcCtD
Avanafil—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000137	0.000592	CcSEcCtD
Avanafil—Rash—Glyburide—type 2 diabetes mellitus	0.000136	0.000588	CcSEcCtD
Avanafil—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000136	0.000587	CcSEcCtD
Avanafil—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000136	0.000587	CcSEcCtD
Avanafil—Vertigo—Ramipril—type 2 diabetes mellitus	0.000136	0.000587	CcSEcCtD
Avanafil—CYP3A4—Estrogen metabolism—GSTM1—type 2 diabetes mellitus	0.000136	0.00651	CbGpPWpGaD
Avanafil—Headache—Glyburide—type 2 diabetes mellitus	0.000135	0.000584	CcSEcCtD
Avanafil—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000134	0.000582	CcSEcCtD
Avanafil—Hypotension—Losartan—type 2 diabetes mellitus	0.000134	0.000581	CcSEcCtD
Avanafil—Palpitations—Ramipril—type 2 diabetes mellitus	0.000133	0.000577	CcSEcCtD
Avanafil—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000132	0.000573	CcSEcCtD
Avanafil—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000132	0.00057	CcSEcCtD
Avanafil—Cough—Ramipril—type 2 diabetes mellitus	0.000132	0.00057	CcSEcCtD
Avanafil—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000132	0.00057	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000131	0.000567	CcSEcCtD
Avanafil—Constipation—Irbesartan—type 2 diabetes mellitus	0.000131	0.000565	CcSEcCtD
Avanafil—Insomnia—Losartan—type 2 diabetes mellitus	0.00013	0.000562	CcSEcCtD
Avanafil—PDE5A—Hemostasis—NOS1—type 2 diabetes mellitus	0.000129	0.00618	CbGpPWpGaD
Avanafil—Chest pain—Ramipril—type 2 diabetes mellitus	0.000129	0.000556	CcSEcCtD
Avanafil—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000129	0.000556	CcSEcCtD
Avanafil—Myalgia—Ramipril—type 2 diabetes mellitus	0.000129	0.000556	CcSEcCtD
Avanafil—Nausea—Glyburide—type 2 diabetes mellitus	0.000128	0.000554	CcSEcCtD
Avanafil—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000128	0.000553	CcSEcCtD
Avanafil—Somnolence—Losartan—type 2 diabetes mellitus	0.000128	0.000553	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000128	0.000552	CcSEcCtD
Avanafil—Asthenia—Valsartan—type 2 diabetes mellitus	0.000127	0.000552	CcSEcCtD
Avanafil—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000126	0.000547	CcSEcCtD
Avanafil—Asthenia—Orlistat—type 2 diabetes mellitus	0.000126	0.000545	CcSEcCtD
Avanafil—Pruritus—Valsartan—type 2 diabetes mellitus	0.000126	0.000544	CcSEcCtD
Avanafil—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000126	0.000544	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PTPN1—type 2 diabetes mellitus	0.000125	0.00602	CbGpPWpGaD
Avanafil—Pruritus—Orlistat—type 2 diabetes mellitus	0.000124	0.000538	CcSEcCtD
Avanafil—Fatigue—Losartan—type 2 diabetes mellitus	0.000124	0.000536	CcSEcCtD
Avanafil—PDE5A—Hemostasis—RASGRP1—type 2 diabetes mellitus	0.000123	0.00592	CbGpPWpGaD
Avanafil—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000123	0.000532	CcSEcCtD
Avanafil—Constipation—Losartan—type 2 diabetes mellitus	0.000123	0.000532	CcSEcCtD
Avanafil—Rash—Gliclazide—type 2 diabetes mellitus	0.000122	0.000528	CcSEcCtD
Avanafil—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000122	0.000527	CcSEcCtD
Avanafil—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000122	0.000526	CcSEcCtD
Avanafil—Headache—Gliclazide—type 2 diabetes mellitus	0.000121	0.000524	CcSEcCtD
Avanafil—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000121	0.000523	CcSEcCtD
Avanafil—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000121	0.000522	CcSEcCtD
Avanafil—Tachycardia—Ramipril—type 2 diabetes mellitus	0.00012	0.00052	CcSEcCtD
Avanafil—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.00012	0.00052	CcSEcCtD
Avanafil—Skin disorder—Ramipril—type 2 diabetes mellitus	0.00012	0.000518	CcSEcCtD
Avanafil—Dizziness—Valsartan—type 2 diabetes mellitus	0.000117	0.000508	CcSEcCtD
Avanafil—Dizziness—Orlistat—type 2 diabetes mellitus	0.000116	0.000502	CcSEcCtD
Avanafil—Asthenia—Metformin—type 2 diabetes mellitus	0.000116	0.000502	CcSEcCtD
Avanafil—Hypotension—Ramipril—type 2 diabetes mellitus	0.000115	0.000498	CcSEcCtD
Avanafil—Nausea—Gliclazide—type 2 diabetes mellitus	0.000115	0.000497	CcSEcCtD
Avanafil—Pruritus—Metformin—type 2 diabetes mellitus	0.000114	0.000495	CcSEcCtD
Avanafil—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000114	0.000492	CcSEcCtD
Avanafil—Vomiting—Valsartan—type 2 diabetes mellitus	0.000113	0.000489	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000112	0.000486	CcSEcCtD
Avanafil—Rash—Valsartan—type 2 diabetes mellitus	0.000112	0.000485	CcSEcCtD
Avanafil—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000112	0.000484	CcSEcCtD
Avanafil—PDE5A—Hemostasis—SOD1—type 2 diabetes mellitus	0.000112	0.00536	CbGpPWpGaD
Avanafil—Vomiting—Orlistat—type 2 diabetes mellitus	0.000112	0.000483	CcSEcCtD
Avanafil—Insomnia—Ramipril—type 2 diabetes mellitus	0.000111	0.000482	CcSEcCtD
Avanafil—Headache—Valsartan—type 2 diabetes mellitus	0.000111	0.000482	CcSEcCtD
Avanafil—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000111	0.000479	CcSEcCtD
Avanafil—Rash—Orlistat—type 2 diabetes mellitus	0.000111	0.000479	CcSEcCtD
Avanafil—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000111	0.000479	CcSEcCtD
Avanafil—Headache—Orlistat—type 2 diabetes mellitus	0.00011	0.000476	CcSEcCtD
Avanafil—Asthenia—Irbesartan—type 2 diabetes mellitus	0.00011	0.000474	CcSEcCtD
Avanafil—Somnolence—Ramipril—type 2 diabetes mellitus	0.00011	0.000474	CcSEcCtD
Avanafil—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—type 2 diabetes mellitus	0.000109	0.00524	CbGpPWpGaD
Avanafil—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000108	0.000469	CcSEcCtD
Avanafil—PDE5A—Hemostasis—GNB3—type 2 diabetes mellitus	0.000108	0.00519	CbGpPWpGaD
Avanafil—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000108	0.000467	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—type 2 diabetes mellitus	0.000108	0.00516	CbGpPWpGaD
Avanafil—Dizziness—Metformin—type 2 diabetes mellitus	0.000107	0.000463	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—type 2 diabetes mellitus	0.000106	0.00511	CbGpPWpGaD
Avanafil—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000106	0.00046	CcSEcCtD
Avanafil—Fatigue—Ramipril—type 2 diabetes mellitus	0.000106	0.00046	CcSEcCtD
Avanafil—PDE5A—Hemostasis—IGF2—type 2 diabetes mellitus	0.000106	0.00509	CbGpPWpGaD
Avanafil—Nausea—Valsartan—type 2 diabetes mellitus	0.000106	0.000457	CcSEcCtD
Avanafil—Constipation—Ramipril—type 2 diabetes mellitus	0.000105	0.000456	CcSEcCtD
Avanafil—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000104	0.000452	CcSEcCtD
Avanafil—Nausea—Orlistat—type 2 diabetes mellitus	0.000104	0.000451	CcSEcCtD
Avanafil—Asthenia—Losartan—type 2 diabetes mellitus	0.000103	0.000446	CcSEcCtD
Avanafil—PDE5A—Hemostasis—APOB—type 2 diabetes mellitus	0.000103	0.00494	CbGpPWpGaD
Avanafil—Vomiting—Metformin—type 2 diabetes mellitus	0.000103	0.000445	CcSEcCtD
Avanafil—Rash—Metformin—type 2 diabetes mellitus	0.000102	0.000441	CcSEcCtD
Avanafil—Dermatitis—Metformin—type 2 diabetes mellitus	0.000102	0.000441	CcSEcCtD
Avanafil—Pruritus—Losartan—type 2 diabetes mellitus	0.000102	0.00044	CcSEcCtD
Avanafil—Headache—Metformin—type 2 diabetes mellitus	0.000101	0.000439	CcSEcCtD
Avanafil—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000101	0.000437	CcSEcCtD
Avanafil—Diarrhoea—Losartan—type 2 diabetes mellitus	9.83e-05	0.000425	CcSEcCtD
Avanafil—Body temperature increased—Ramipril—type 2 diabetes mellitus	9.74e-05	0.000422	CcSEcCtD
Avanafil—Vomiting—Irbesartan—type 2 diabetes mellitus	9.71e-05	0.00042	CcSEcCtD
Avanafil—Rash—Irbesartan—type 2 diabetes mellitus	9.63e-05	0.000417	CcSEcCtD
Avanafil—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.62e-05	0.000416	CcSEcCtD
Avanafil—Nausea—Metformin—type 2 diabetes mellitus	9.61e-05	0.000416	CcSEcCtD
Avanafil—Headache—Irbesartan—type 2 diabetes mellitus	9.56e-05	0.000414	CcSEcCtD
Avanafil—Dizziness—Losartan—type 2 diabetes mellitus	9.5e-05	0.000411	CcSEcCtD
Avanafil—PDE5A—Hemostasis—CD36—type 2 diabetes mellitus	9.35e-05	0.00449	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PPP2CA—type 2 diabetes mellitus	9.23e-05	0.00443	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—PPARGC1A—type 2 diabetes mellitus	9.23e-05	0.00443	CbGpPWpGaD
Avanafil—Vomiting—Losartan—type 2 diabetes mellitus	9.14e-05	0.000395	CcSEcCtD
Avanafil—Nausea—Irbesartan—type 2 diabetes mellitus	9.07e-05	0.000392	CcSEcCtD
Avanafil—Rash—Losartan—type 2 diabetes mellitus	9.06e-05	0.000392	CcSEcCtD
Avanafil—Dermatitis—Losartan—type 2 diabetes mellitus	9.05e-05	0.000392	CcSEcCtD
Avanafil—Headache—Losartan—type 2 diabetes mellitus	9e-05	0.00039	CcSEcCtD
Avanafil—Asthenia—Ramipril—type 2 diabetes mellitus	8.84e-05	0.000383	CcSEcCtD
Avanafil—Pruritus—Ramipril—type 2 diabetes mellitus	8.72e-05	0.000377	CcSEcCtD
Avanafil—Nausea—Losartan—type 2 diabetes mellitus	8.53e-05	0.000369	CcSEcCtD
Avanafil—PDE5A—Hemostasis—MMP1—type 2 diabetes mellitus	8.52e-05	0.00409	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP2E1—type 2 diabetes mellitus	8.45e-05	0.00405	CbGpPWpGaD
Avanafil—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.43e-05	0.000365	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1A2—type 2 diabetes mellitus	8.35e-05	0.00401	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—type 2 diabetes mellitus	8.27e-05	0.00397	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CALM1—type 2 diabetes mellitus	8.27e-05	0.00397	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—type 2 diabetes mellitus	8.17e-05	0.00392	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—APOA1—type 2 diabetes mellitus	8.15e-05	0.00391	CbGpPWpGaD
Avanafil—Dizziness—Ramipril—type 2 diabetes mellitus	8.15e-05	0.000353	CcSEcCtD
Avanafil—Vomiting—Ramipril—type 2 diabetes mellitus	7.83e-05	0.000339	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PRKCB—type 2 diabetes mellitus	7.77e-05	0.00373	CbGpPWpGaD
Avanafil—Rash—Ramipril—type 2 diabetes mellitus	7.77e-05	0.000336	CcSEcCtD
Avanafil—Dermatitis—Ramipril—type 2 diabetes mellitus	7.76e-05	0.000336	CcSEcCtD
Avanafil—Headache—Ramipril—type 2 diabetes mellitus	7.72e-05	0.000334	CcSEcCtD
Avanafil—PDE5A—Hemostasis—NOS2—type 2 diabetes mellitus	7.68e-05	0.00369	CbGpPWpGaD
Avanafil—Nausea—Ramipril—type 2 diabetes mellitus	7.32e-05	0.000317	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—MAT1A—type 2 diabetes mellitus	7.25e-05	0.00348	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—type 2 diabetes mellitus	7.07e-05	0.00339	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	6.83e-05	0.00328	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IGF1—type 2 diabetes mellitus	6.81e-05	0.00327	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—AKT2—type 2 diabetes mellitus	6.81e-05	0.00327	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CAT—type 2 diabetes mellitus	6.78e-05	0.00325	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	6.75e-05	0.00324	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	6.74e-05	0.00323	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	6.71e-05	0.00322	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	6.66e-05	0.0032	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SERPINE1—type 2 diabetes mellitus	6.47e-05	0.00311	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ALB—type 2 diabetes mellitus	6.46e-05	0.0031	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3R1—type 2 diabetes mellitus	6.18e-05	0.00296	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS3—type 2 diabetes mellitus	6.18e-05	0.00296	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	5.84e-05	0.0028	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	5.54e-05	0.00266	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	5.47e-05	0.00263	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SRC—type 2 diabetes mellitus	4.57e-05	0.00219	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VEGFA—type 2 diabetes mellitus	4.45e-05	0.00214	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TGFB1—type 2 diabetes mellitus	4.08e-05	0.00196	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—MTR—type 2 diabetes mellitus	3.68e-05	0.00177	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP11A1—type 2 diabetes mellitus	3.56e-05	0.00171	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	3.51e-05	0.00169	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP2E1—type 2 diabetes mellitus	2.94e-05	0.00141	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP1A2—type 2 diabetes mellitus	2.91e-05	0.0014	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	2.9e-05	0.00139	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	2.87e-05	0.00138	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—AKT1—type 2 diabetes mellitus	2.84e-05	0.00136	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	2.23e-05	0.00107	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	2.2e-05	0.00106	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	1.7e-05	0.000816	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	1.49e-05	0.000713	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	1.49e-05	0.000713	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	1.41e-05	0.000676	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	1.41e-05	0.000676	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	1.34e-05	0.000645	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.24e-05	0.000595	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.24e-05	0.000595	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.2e-05	0.000575	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.2e-05	0.000575	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.2e-05	0.000575	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.2e-05	0.000575	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.2e-05	0.000575	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.16e-05	0.000557	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.1e-05	0.000526	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.1e-05	0.000526	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.07e-05	0.000512	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.02e-05	0.000489	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.02e-05	0.000489	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.02e-05	0.000489	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	9.76e-06	0.000469	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	9.76e-06	0.000469	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	9.4e-06	0.000451	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	9.4e-06	0.000451	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	9.23e-06	0.000443	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	9.08e-06	0.000436	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	9.08e-06	0.000436	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	9.08e-06	0.000436	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	8.53e-06	0.00041	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	7.99e-06	0.000384	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	7.72e-06	0.00037	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	7.72e-06	0.00037	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	7.72e-06	0.00037	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	7.72e-06	0.00037	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	7.4e-06	0.000355	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	6.88e-06	0.00033	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	6.42e-06	0.000308	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	6.29e-06	0.000302	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	6.29e-06	0.000302	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	6.17e-06	0.000296	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	6.13e-06	0.000294	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	6.13e-06	0.000294	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	6.13e-06	0.000294	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	6.09e-06	0.000292	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	5.98e-06	0.000287	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	5.92e-06	0.000284	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	5.5e-06	0.000264	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	5.5e-06	0.000264	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	5.5e-06	0.000264	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.4e-06	0.000259	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.35e-06	0.000257	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.23e-06	0.000251	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.03e-06	0.000241	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.97e-06	0.000239	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.97e-06	0.000239	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.77e-06	0.000229	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.77e-06	0.000229	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.11e-06	0.000197	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.11e-06	0.000197	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.09e-06	0.000196	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.04e-06	0.000194	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.92e-06	0.000188	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.81e-06	0.000183	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.74e-06	0.00018	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.66e-06	0.000176	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.65e-06	0.000175	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.55e-06	0.000171	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.51e-06	0.000168	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.37e-06	0.000162	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.3e-06	0.000159	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.2e-06	0.000154	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.15e-06	0.000151	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.14e-06	0.000151	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.1e-06	0.000149	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.73e-06	0.000131	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.68e-06	0.000129	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.46e-06	0.000118	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.35e-06	0.000113	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.35e-06	0.000113	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.15e-06	0.000103	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.08e-06	5.18e-05	CbGpPWpGaD
